	DEPARTMENT OF COMMERCE PATENT AND TRADEMARK	OFFICE ATTORNEYS DOCKET NUMBER			
DESIGNATED/ELECT	R TO THE UNITED STATES FED OFFICE (DO/EO/US) NG UNDER 35 U.S.C. 371	11336.0027USWO			
		U.S. APPLICATION NOTIFICATION 10 11 10 11 15 17 10 6 1 9			
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED			
PCT/IN03/00156	April 16, 2003	April 15, 2002			
TITLE OF INVENTION					
SUBSTANTIALLY PURE ANTIHISTAM	INIC COMPOUND				
APPLICANT(S) FOR DO/EO/US					
THENNATI et al.					
Applicant herewith submits to the United States	Designated/Elected Office (DO/EO/US) the following	lowing items and other information:			
 3. [X] This express request to begin national e examination until the expiration of the a 4. [X] A proper Demand for International Prel 	JENT submission of items concerning a filing usexamination procedures (35 U.S.C. 371(f)) at an applicable time limit set in 35 U.S.C. 371(b) and distinguishing examination was made by the 19th model.	ny time rather than delay nd PCT Articles 22 and 39(I).			
b. [X] has been transmitted by the In c. [] is not required, as the app A translation of the International A	red only if not transmitted by the International Enternational Bureau. plication was filed in the United States Receivin Application into English (35 U.S.C. 371(c)(2)).	ng Office (RO/US)			
a. [] are transmitted herewith (b. [] have been transmitted by	national Application under PCT Article 19 (35 U (required only if not transmitted by the Internation the International Bureau. vever, the time limit for making such amendment not be made.	ional Bureau).			
8. [] A translation of the amendments to	the claims under PCT Article 19 (35 U.S.C. 37)	71(c)(3)).			
9. [X] An unsigned oath or declaration of the i	inventor(s) (35 U.S.C. 371 (c)(4)).	,			
10. [] A translation of the annexes to the (35 U.S.C. 371(c)(5)).	International Preliminary Examination Report (under PCT Article 36			
Items 11. to 16. below concern document(s) or 11. [X] An Information Disclosure Statement up					
12. [] An assignment document for record	rding. A separate cover sheet in compliance with	h 37 CFR 3.28 and 3.31 is included.			
13. [X] A FIRST preliminary amendment. A SECOND of SUBSEQUENT pr	reliminary amendment.				
14. [] A substitute specification.					
15. [] A change of power of attorney and	/or address letter.				
16. [X] Other items or information: Application PCT/IB/345, Corrected versions of Form PCT/IB 2003/086275 A3, Form PCT/ISA/210, Form PCT/I	B/301, Form PCT/ISA/220, Form PCT/ISA/202	2, Form PCT/IB/308, Form PCT/IB/332, WO			

10/510619

Applicant:

THENNATI et al.

DT04 Rec'd PCT/PTO 0 7 OCT 2004

Docket:

11336.0027USWO

Title:

SUBSTANTIALLY PURE ANTIHISTAMINIC COMPOUND

CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number: EV 408493948 US

Date of Deposit: October 7, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service

under 37 CFR 1/10 and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name: David Ortiz

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

1

We are transmitting herewith the attached:

☐ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.10.

National Stage PCT Patent Application: Spec. 12 pgs; 20 claims; Abstract 1 pgs. The fee has been calculated as shown below in the 'Claims as Filed' table.

An unsigned Combined Declaration and Power of Attorney

A check in the amount of \$950.00 to cover the Filing Fee

Information Disclosure Statement, Form 1449, 1 reference(s).

Application Data Sheet, 5 pages.

Other: Form PTO-1390, Preliminary Amendment (8 pages), Form PCT/RO/101, Form PCT/IB/301, Form PCT/IB/345, Corrected version of Form PCT/IB/301, Form PCT/ISA/220, Form PCT/ISA/202, Form PCT/IB/308, Form PCT/IB/332, WO 2003/086275 A3, Form PCT/ISA/210, Form PCT/IPEA.401, Form PCT/IPEA/402, Form PCT/IPEA/416, Form PCT/IPEA/409

Return postcard

CLAIMS AS FILED

Number of Claims Filed		In Excess of:		Number Extra		Rate		Fee
Basic Filing Fee	++	11. 41,000		Datia	 			\$950.00
Total Claims	1-1-	· · · · · · · · · · · · · · · · · · ·						
20	1-1	20	=	0	х	18.00	=	\$0.00
Independent Claims								
2	1-1	3	=	0	х	86.00	11	\$0.00
MULTIPLE DEPENDENT CLAIM FEE							\$0.00	
TOTAL FILING FEE							\$950.00	

Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.

P.O. Box 2903, Minneapolis, MN 55402-0903

(612) 332-5300

Name: Douglas P. Mueller

Reg. No.: 30,300 Initials: DPM/sbd

23552

PATENT TRADEMARK OFFICE

DOCKET NOTIFICATION SLIP

TO: PATENT DOCKETING

Applicant:

THENNATI et al.

Title:

SUBSTANTIALLY PURE ANTIHISTAMINIC COMPOUND

Docket:

11336.0027USWO

Express Mail No.: EV 408493948 US Date of Deposit: October 7, 2004

Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.10.

National Stage PCT Patent Application: Spec. 12 pgs; 20 claims; Abstract 1 pgs.

An unsigned Combined Declaration and Power of Attorney

A check in the amount of \$950.00 to cover the Filing Fee

Information Disclosure Statement, Form 1449, 1 reference(s).

Application Data Sheet, 5 pages.

☑ Other: Form PTO-1390, Preliminary Amendment (8 pages), Form PCT/RO/101, Form PCT/IB/301, Form PCT/IB/345, Corrected version of Form PCT/IB/301, Form PCT/ISA/220, Form PCT/ISA/202, Form PCT/IB/308, Form PCT/IB/332, WO 2003/086275 A3, Form PCT/ISA/210, Form PCT/IPEA.401, Form PCT/IPEA/402, Form PCT/IPEA/416, Form PCT/IPEA/409

Return postcard

DPM/sbd NO FF